PHELAN-MCDERMID SYNDROME
Clinical trials for PHELAN-MCDERMID SYNDROME explained in plain language.
Never miss a new study
Get alerted when new PHELAN-MCDERMID SYNDROME trials appear
Sign up with your email to follow new studies for PHELAN-MCDERMID SYNDROME, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Hope for rare genetic disorder: new drug trial targets core symptoms
Disease control Recruiting nowThis study tests an oral drug called NNZ-2591 in 160 children aged 3 to 12 with Phelan-McDermid syndrome, a rare genetic condition. The drug is compared to a placebo to see if it improves communication and daily function. The trial is double-blind, meaning neither the families no…
Matched conditions: PHELAN-MCDERMID SYNDROME
Phase: PHASE3 • Sponsor: Neuren Pharmaceuticals Limited • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New drug shows promise for rare genetic disorder in kids
Disease control Recruiting nowThis phase 3 study is testing an oral drug called NNZ-2591 in 180 children aged 3 to 12 with Phelan-McDermid syndrome, a rare genetic condition that causes developmental delays and other challenges. The main goal is to see if the drug is safe and tolerable over the long term. Res…
Matched conditions: PHELAN-MCDERMID SYNDROME
Phase: PHASE3 • Sponsor: Neuren Pharmaceuticals Limited • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Gene therapy trial hopes to tackle rare Autism-Linked condition
Disease control Recruiting nowThis early-stage trial tests a single dose of JAG201 gene therapy, given directly into the brain fluid, for people with SHANK3 haploinsufficiency (Phelan-McDermid syndrome), a rare genetic condition causing developmental delays and autism-like symptoms. The study includes childre…
Matched conditions: PHELAN-MCDERMID SYNDROME
Phase: PHASE1, PHASE2 • Sponsor: Jaguar Gene Therapy, LLC • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC